{"id":"W4765708","doi":"10.2165/00044011-200929050-00003","title":"Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bayer Canada; Astellas Pharma; GlaxoSmithKline; Pfizer","keywords":"Tolterodine; Overactive bladder; Solifenacin; Medicine; Tolerability; Urology; Adverse effect; Nocturia; Urinary urgency; Internal medicine; Urinary system","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003762235,0.0002524931,0.0005338159,0.0001515397,0.00008146766,0.00003562965,0.00005170804,0.0001088778,0.00003399595],"category_scores_gemma":[0.001073514,0.0001778989,0.00007217674,0.0002223388,0.00007604346,0.0002742047,0.0000427505,0.0003707776,0.00001827496],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001458111,"about_ca_system_score_gemma":0.0001847946,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004137905,"about_ca_topic_score_gemma":0.00007319658,"domain_scores_codex":[0.9975187,0.0003795943,0.0007499419,0.000602639,0.000436802,0.000312367],"domain_scores_gemma":[0.9980136,0.0007213528,0.0001790075,0.0003462425,0.0001436126,0.0005962037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001855431,0.00118606,0.9176801,0.000007972606,0.000142487,0.0001023874,0.002238672,0.00001541416,0.0001953746,0.000006585274,0.0002917317,0.07627782],"study_design_scores_gemma":[0.006829818,0.003478243,0.9870467,0.0001593281,0.0001008809,0.000003691485,0.0001629427,0.0003478911,0.0005089863,0.001050857,0.0001023586,0.0002082804],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931221,0.00004985345,0.00003057798,0.005130576,0.00008009715,0.00129858,0.00003674304,0.00004779439,0.0002036876],"genre_scores_gemma":[0.9957789,0.0000440045,0.0009366435,0.002673044,0.00006968401,0.00003661209,0.0002904014,0.00002199352,0.0001487083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07606954,"threshold_uncertainty_score":0.7254505,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03128411834866037,"score_gpt":0.3371129593835576,"score_spread":0.3058288410348973,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}